ReviewAnnals of hematology2026
Biomarkers and advances in AML-MRC: from bench to bedside.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) represents a high-risk subtype of AML, characterized by poor prognosis and limited therapeutic options. Recent updates in the WHO and ICC classifications have redefined AML-MRC, emphasizing molecular and cytogenetic criteria over morphological features alone. This review provides a comprehensive overview of the pathogenesis, key biomarkers, and diagnostic innovations in AML-MRC, highlighting the role of genetic mutations (e.g., TP53, RUNX1, and splicing factors), cytogenetic abnormalities, and immune microenvironment alterations. We explore advanced diagnostic techniques such as next-generation sequencing (NGS), minimal residual disease (MRD) monitoring, and functional precision medicine (FPM), which are revolutionizing disease stratification and treatment selection. Additionally, we discuss emerging therapies, including CPX-351, hypomethylating agents (HMAs), targeted inhibitors (e.g., FLT3 and IDH1/2 inhibitors), and immunotherapies, while addressing the challenges of treatment resistance and relapse. The integration of multi-omics technologies and liquid biopsies offers promising avenues for personalized medicine, enabling dynamic monitoring and tailored therapeutic strategies. Finally, we outline future directions, emphasizing the potential of artificial intelligence and collaborative efforts to overcome current limitations and improve patient outcomes. This review underscores the importance of precision medicine in transforming the management of AML-MRC, bridging the gap between bench research and clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.